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H1N1 infection in England: an observational 
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Summary
Background Young people (aged 0–18 years) have been disproportionately aﬀ ected by pandemic inﬂ uenza A H1N1 
infection. We aimed to analyse paediatric mortality to inform clinical and public health policies for future inﬂ uenza 
seasons and pandemics.
Methods All paediatric deaths related to pandemic inﬂ uenza A H1N1 infection from June 26, 2009, to March 22, 2010 
in England were identiﬁ ed through daily reporting systems and cross-checking of records and were validated by 
conﬁ rmation of inﬂ uenza infection by laboratory results or death certiﬁ cates. Clinicians responsible for each 
individual child provided detailed information about past medical history, presentation, and clinical course of the 
acute illness. Case estimates of inﬂ uenza A H1N1 were obtained from the Health Protection Agency. The primary 
outcome measures were population mortality rates and case-fatality rates.
Findings 70 paediatric deaths related to pandemic inﬂ uenza A H1N1 were reported. Childhood mortality rate was 
6 per million population. The rate was highest for children aged less than 1 year. Mortality rates were higher for 
Bangladeshi children (47 deaths per million population [95% CI 17–103]) and Pakistani children (36 deaths per million 
population [18–64]) than for white British children (4 deaths per million [3–6]). 15 (21%) children who died were 
previously healthy; 45 (64%) had severe pre-existing disorders. The highest age-standardised mortality rate for a pre-
existing disorder was for chronic neurological disease (1536 per million population). 19 (27%) deaths occurred before 
inpatient admission. Children in this subgroup were signiﬁ cantly more likely to have been healthy or had only mild 
pre-existing disorders than those who died after admission (p=0·0109). Overall, 45 (64%) children had received 
oseltamivir: seven within 48 h of symptom onset.
Interpretation Vaccination priority should be for children at increased risk of severe illness or death from inﬂ uenza. 
This group might include those with speciﬁ ed pre-existing disorders and those in some ethnic minority groups. Early 
pre-hospital supportive and therapeutic care is also important.
Funding Department of Health, UK
Introduction
Seasonal inﬂ uenza can cause infection and treatment 
in hospital in children, but mortality is low and the 
viruses predominantly aﬀ ect people older than 65 years 
of age.1 However, children have been dispropor-
tionately aﬀ ected by pandemic inﬂ uenza A H1N1 
compared with older age-groups,2 and this infection 
has caused severe disease and death in a minority 
of children.3,4
Despite national and global reports of the complications 
of pandemic inﬂ uenza A H1N1, a detailed analysis of 
paediatric mortality has not been provided. Following 
the outset of the pandemic in England in April, 2009, 
we initiated a conﬁ dential investigation into all result-
ing deaths.5 This investigation has provided a real-time 
and comprehensive system of national surveillance, 
which we have used to examine paediatric deaths in 
depth. We aimed to provide important evidence to 
strengthen clinical and public health policies for 
children during forthcoming inﬂ uenza seasons and 
future pandemics.
Methods
Study population
Mandatory daily reporting systems were established for 
all suspected and conﬁ rmed deaths from pandemic 
inﬂ uenza A H1N1 in England. Further deaths were 
identiﬁ ed through cross-checking of records held by the 
Regional Directors of Public Health and by the Health 
Protection Agency’s inﬂ uenza reference centres. For all 
reported cases, a member of the Chief Medical Oﬃ  cer’s 
clinical team contacted the responsible senior physician 
to obtain further details. A death was conﬁ rmed as related 
to pandemic inﬂ uenza A H1N1 if there was laboratory 
evidence of H1N1 infection or if H1N1 infection (or 
synonym) was recorded on the death certiﬁ cate. Further 
details of the method of death ascertainment have been 
reported previously.5
Study design
All validated deaths in children aged less than 18 years 
were extracted from this dataset. The clinician responsible 
for each individual child was interviewed by telephone by 
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a paediatrician working for the Chief Medical Oﬃ  cer. The 
data collection proforma is available in the web appendix. 
Information gathered included: demographic charac-
teristics, pre-existing disorders and past medical history, 
and presenting symptoms and clinical course. If results 
of microbiological, haematological, and radio logical 
investigations were not immediately available from 
clinicians, they were obtained from hospital or public 
health laboratories. Information was cross-checked with 
coroners’ reports. In cases for whom past medical 
information was unavailable, supplementary information 
was obtained from the general practitioner or local 
hospital. When the presence or absence of a symptom or 
pre-existing disorder was not speciﬁ ed, we assumed that 
none was present.
Collection and processing of data was undertaken 
under the Health Service (Control Of Patient Information) 
Regulations 2002 (Statutory Instrument 1438) for the 
purpose of communicable disease control in England. 
Therefore, consent from patients was not needed.
The primary outcome measures were population 
mortality rates (by age-group and for children with pre-
existing disorders) and case-fatality rates. Secondary 
measures included presenting symptoms and signs, pre-
existing disorders, and subsequent com plications.
The physical status classiﬁ cation scale of the American 
Society of Anaesthesiologists6 was used to establish the 
general health of the children before acute illness. 
Children were classiﬁ ed as being healthy (grade one) or 
having mild (grade two), moderate (grade three), or 
severe (grade four or ﬁ ve) pre-existing systemic disease. 
Speciﬁ c pre-existing disorders (eg, developmental delay) 
and the severity of presenting symptoms (eg, dyspnoea) 
were classiﬁ ed as absent, mild, moderate, or severe by 
the clinicians who cared for the child.
Recurrent hospital admission was deﬁ ned as an 
inpatient stay for longer than 6 weeks, or greater than 
four admissions in the previous year. Bacterial sepsis was 
conﬁ rmed if bacterial growth was identiﬁ ed on laboratory 
culture after clinical suspicion of bacterial infection. 
Bacterial sepsis was presumed by clinicians if systemic 
features of bacterial infection were present (ie, rising 
inﬂ ammatory markers or signs of focal infection) but 
bacterial cultures were negative.
Age-stratiﬁ ed cases of pandemic inﬂ uenza A H1N1 were 
estimated every week by the Health Protection Agency 
with methods described previously.5 Population numbers 
for England by age-group and ethnic origin are estimated 
by the Oﬃ  ce for National Statistics. The most recent 
estimates were used to provide denominators for pop-
ulation mortality rates stratiﬁ ed by age7 and ethnic origin.8
To assess the risk of death associated with pre-existing 
disorders that would confer an increased risk of seasonal 
inﬂ uenza, data from the Department of Health vaccine 
monitoring system were used to estimate the number of 
people in England aﬀ ected by these disorders. This 
system uses primary care records to estimate the number 
of patients with speciﬁ c grouped disorders by age band. 
These estimates are available only for children aged at 
least 6 months. Deaths in those aged less than 6 months 
were therefore excluded from this analysis.
Statistical analyses
Case-fatality rates were calculated for every age-group 
with Health Protection Agency midpoint case estimates. 
The upper and lower estimates by age were used to 
calculate lower and upper estimates for the case-fatality 
rates, respectively. A 95% conﬁ dence interval was 
calculated around these estimates, to account for the 
uncertainty around the number of cases. The case-fatality 
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Data for case estimates provided by the Health Protection Agency.
For more on these Regulations 
see http:www.legislation.gov.uk/
UKsi/2002/1438/contents/made
See Online for webappendix
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ranges presented refer to the upper 95% conﬁ dence 
interval of the upper case-fatality rate estimate and the 
lower 95% conﬁ dence interval of the lower estimate. 
IQRs were calculated for all other ranges other than case-
fatality rates. Population mortality rates were calculated 
by age and ethnic group. Mortality rates for speciﬁ ed pre-
existing disorders were calculated and age standardised 
to the English population.
Fisher’s exact test or the χ² test with Yates’ correction 
were used to test signiﬁ cance of data for categorical data 
(eg, ethnic origin, those with bacterial sepsis, or those on 
pre-hospital antivirals). The Mann–Whitney U test was 
used for non-parametric data. Analyses were done with 
SPSS (version 12.0) and R (version 2.9.2).
Role of the funding source
This work was done as part of the Department of Health’s 
public health response to the inﬂ uenza pandemic in 
England. No additional funding was sought. The funding 
source had no direct involvement in study design; in the 
collection, analysis, and interpretation of data; in the 
writing of the report; or in the decision to submit the paper 
for publication. Both authors had full access to all the data 
in the study and the corresponding author had ﬁ nal 
responsibility for the decision to submit for publication.
Results
A total of 70 paediatric deaths related to pandemic 
inﬂ uenza A H1N1 occurred in England during the study 
period (ﬁ gure). All cases were laboratory conﬁ rmed. 
Complete demographic and clinical details were obtained 
for all deaths. Deaths were evenly distributed between 
male (31) and female (39) children. Median age at death 
was 7 years (range 0∙25–17 years; IQR 2–12 years). Case-
fatality and population mortality rates were highest in 
children aged less than 1 year (table 1).
Bangladeshi or British Bangladeshi children (47 deaths 
per million population [95% CI 17–103; n=6]) and 
Pakistani or British Pakistani children (36 [18–64; n=11]) 
had the highest population mortality rates, compared 
with white British children (4 ([3–6; n=37]). Pre-existing 
health status did not diﬀ er between ethnic groups. 
Calculation of case-fatality rates by ethnic group was not 
possible because estimates of case numbers were not 
available by ethnic origin.
Predominantly respiratory symptoms were reported on 
presentation in 53 of 70 (76%) deaths. Fever, cough, and 
dyspnoea were the most frequent symptoms on 
presentation (table 2). The extent of dyspnoea was rated 
by clinicians as moderate in 28 (40%) and severe in 
12 (17%) deaths. Mainly gastrointestinal symptoms were 
described in two (3%) deaths. Among hospital deaths, 
most cases (42 of 67; 63%) initially presented to the 
emergency department with symptoms of inﬂ uenza and 
16 (24%) presented in cardiorespiratory arrest. The rest 
presented in shock (ﬁ ve; 7%), status epilepticus (three; 
4%), or with non-speciﬁ c symptoms (one; 1%).
Deaths were categorised into those who deteriorated 
rapidly and died before, or at the point of, hospital 
admission (early deaths [19 of 70; 27%]), and those who 
died after hospital admission (late deaths [51; 73%]). The 
early deaths group had a signiﬁ cantly greater proportion 
of children with no, or mild, pre-existing disorders 
(table 3). Of the early deaths, nine of 19 (47%) had 
consulted a general practitioner during their illness.
Before presentation, fever (47 of 51 vs 13 of 19, p=0∙020 
[Fisher’s test]) and dyspnoea (40 of 51 vs six of 19, p=0∙002) 
were more common among late deaths than among early 
deaths. Nausea and vomiting were less common among 
late deaths (seven of 51 vs seven of 19, p=0·045). Frequency 
of other symptoms did not diﬀ er between the two groups.
Children with severe pre-existing disorders accounted 
for 64% (45 of 70) of deaths. However, 21% (15 of 70) of 
children who died were previously healthy. Mild pre-
existing disorders were present in 3% (two) of deaths and 
moderate disorders in 11% (eight) of deaths. For those 
with data available, 36% (23 of 62) had a history of 
recurrent hospital admissions. For most deaths in 
children aged less than 2 years, moderate or severe pre-
existing disorders had been reported (87%; 13 of 15). In 
those older than 2 years, 73% (40 of 55) had moderate or 
severe pre-existing disorders.
Chronic neurological, gastrointestinal, or respiratory 
disease were all present in more than half of all deaths 
(table 4). Of those with chronic neurological disease, 
19 had spastic quadriplegic cerebral palsy. Severe 
Number of deaths
Fever 60 (86%)
Cough 47 (67%)
Dyspnoea 46 (66%)
Dehydration 18 (26%)
Altered mental status or encephalopathy 17 (24%)
Diarrhoea 15 (21%)
Nausea or vomiting 14 (20%)
Seizure or convulsion 5 (7%)
Headache 4 (6%)
Sore throat 4 (6%)
Table 2: Frequency of presenting symptoms and signs among children 
who died from pandemic inﬂ uenza A H1N1 infection
Number 
of deaths
Fatality rate per 100 000 cases of pandemic 
inﬂ uenza A H1N1 (range)
Mortality rate per 
million population 
(95% CI)
< 1 year 9 151 (34–635) 14 (6–26)
1–4 years 15 33 (9–114) 6 (3–10)
5–9 years 22 17 (5–54) 8 (5–12)
10–15 years 15 10 (3–35) 4 (2–7)
16–17 years 9 26 (6–102) 7 (3–13)
0–17 years 70 19 (7–51) 6 (5–8)
Table 1: Case-fatality rates for pandemic inﬂ uenza A H1N1 infection and population mortality rates by 
age in England from June 26, 2009, to March 22, 2010
Articles
www.thelancet.com   Vol 376   November 27, 2010 1849
gastro-oesophageal reﬂ ux was reported in 11 of the 
70 (16%) deaths. Regular gastrostomy or nasogastric 
feeding took place in 41 of 70 (59%) deaths. A diagnosis 
of asthma (requiring any treatment) was reported in 
ﬁ ve of 70 (7%) deaths. Complex congenital cardiac 
disease was reported in eight of 70 (11%) deaths. Almost 
a quarter of all children had been born prematurely 
(17 of 70; median gestation 32 weeks, IQR 27·5–35). 
48 (69%) children who died had developmental delay, 
which had been severe in 31 (44%). Of the 46 children 
of school age (5–18 years), 23 had attended a school for 
children with special needs.
Death rates from pandemic inﬂ uenza A H1N1 for 
children with pre-existing disorders were higher than for 
healthy children. Chronic neurological disease and 
kidney disease conferred the highest risk of any of the 
disorders studied (table 5). The absence of denominator 
data prevented the calculation of an age-standardised 
mortality rate for gastrointestinal disease. Two children 
with severe underlying disorders received the pandemic 
inﬂ uenza A H1N1 vaccine 48 h before developing their 
terminal illness. No other child was vaccinated against 
pandemic inﬂ uenza A H1N1.
Median duration from symptom onset to admission (or 
death if not formally admitted to hospital) was 2 days 
(IQR 1–5). Five children with inter-current infection 
contracted during long-term hospital stays were not 
included in this calculation. Median time from symptom 
onset to death was 7∙5 days (IQR 3–13). Of the children 
who died, 40 were admitted to critical care units (38 to 
intensive care; two to high-dependency units). Of these, 
27 were transferred from other hospitals for specialist care. 
Transfer to critical care occurred a median of 1 day (IQR 
0–2) after hospital admission. In the children admitted to 
critical care, death occurred a median of 6 days later (IQR 
2–11). Within the hospital, the critical care facility was most 
commonly the place of death (40 of 67; 60%), followed by 
the emergency department (17 of 67; 25%).
Organ failure occurred frequently. 40 (57%) children 
developed respiratory failure that needed mechanical 
ventilation: seven needed non-invasive ventilation, ten 
invasive positive pressure ventilation, 21 high-frequency 
oscillation, and two extra-corporeal membrane 
oxygenation. High ventilation pressures were usually 
needed and pneumothoraces occurred in six of the 
40 (15%) children, all of whom had insertion of a chest 
drain. Intracerebral haemorrhage arose secondary to extra-
corporeal membrane oxygenation in one child. Circulatory 
failure needing inotropic support occurred in 30 of 
70 (43%) children. Acute renal failure necessitated renal 
replacement therapy (haemoﬁ ltration or haemodialysis) 
in ﬁ ve of 70 (7%) children. Acute haematological 
abnormalities were recorded in 25 (36%) children before 
death. These abnormalities were thrombocytopenia (16; 
23%), lymphopenia (14; 20%), neutrophilia (three; 4%), 
neutropenia (two; 3%), pancytopenia (two; 3%), and 
disseminated intravascular coagulation (two; 3%). 
45 of 70 (64%) children received oseltamivir—seven 
within 48 h of symptom onset (median 5 days [IQR 3–7·75] 
between symptom onset and treatment with antiviral 
drugs) and three before admission. Oseltamivir resistance 
was recorded in two children—one ante-mortem. Viral 
Number of deaths with 
pre-existing disorders 
(n=70)
Median age at death 
(years; IQR)
Any chronic respiratory disease 37 (53%) 7 (2–12)
Chronic lung disease 13 (19%) 4 (1–5)
Home oxygen 12 (17%) 4 (0·54–8)
Scoliosis with restrictive lung disease 10 (14%) 12 (9·5–12)
Pulmonary hypertension 6 (9%) 1·4 (0·65–11)
Tracheostomy 6 (9%) 6 (2·25–10·25)
Asthma needing preventive therapy 4 (6%) 11 (8–14)
Home ventilation 3 (4%) 11 (5·6–11)
Any chronic cardiac disease 17 (24%) 5 (1–14)
Congenital cardiac disease 12 (17%) 1·6 (0·77–10)
Cardiomyopathy 3 (4%) 16 (12–16)
Any chronic gastrointestinal disease or feeding problem 41 (59%) 6 (1·5–10)
Exclusive gastrostomy or nasogastric feeding 33 (47%) 6 (2–9)
Gastro-oesophageal reﬂ ux 30 (43%) 7 (8–9·8)
Unsafe swallow 24 (34%) 7 (3·8–9)
Any chronic neurological disease 38 (54%) 7 (2–9·8)
Cerebral palsy 22 (31%) 7 (4–9)
Epilepsy 22 (31%) 8 (6–12)
Other
Any chronic endocrine disease 7 (10%) 6 (2·7–13)
Any chronic kidney disease 4 (6%) 7·5 (1·42–7)
Any chronic haematological disease 5 (7%) 16 (13–16)
Any chromosomal disorder 5 (7%) 14 (8–16)
Any malignant disease 1 (1%) 16*
*No IQR as only one child in this group.
Table 4: Frequency of pre-existing disorders in paediatric deaths related to pandemic inﬂ uenza A 
H1N1 infection
Early death group 
(n=19)
Late death group 
(n=51)
p value
Median age (years; IQR) 6 (2–14) 7 (2·5–12) 0·9761*
Ethnic origin
White British 12 (63%) 25 (49%) 0·7547†
Asian or Asian British (any) 6 (32%) 21 (41%)
Black or Black British (any) 1 (5%) 3 (6%) 
Healthy or mild pre-existing disorders 9 (47%) 8 (16%) 0·0109‡
Presumed or conﬁ rmed bacterial sepsis 9 (47%) 19 (37%) 0·5842‡
Pre-hospital antivirals 2 (10%) 1 (2%) 0·1770‡
Duration from symptom onset to death (days; 
median, IQR)
2 (1–2·5) 10 (5·5–16·5) <0·0001*
Duration from symptom onset to ﬁ rst medical 
consult (days; median, IQR)
1 (0·25–2) 2 (0–3·75) 0·4533*
Data are number of patients (%) unless otherwise stated. *Mann-Whitney U test; †χ2 with Yates correction; ‡Fisher’s test.
Table 3: Characteristics of children presenting with rapid deterioration leading to death before, or at the 
point of, hospital admission (early death) and of those who died after hospital admission (late death)
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pneumonitis was reported in 29 of 70 (41%) children and 
bacterial pneumonia in 20 of 70 (29%). Bacterial co-
infection was clinically presumed in 14 (20%) deaths and 
conﬁ rmed in a further 14. The most common sites of 
bacterial infection were the lung (20), blood (six), and 
cerebrospinal ﬂ uid (two). Pathogens most frequently 
isolated were group A Streptococcus (three cases), 
S pneumoniae (three cases), S aureus (three cases), and 
Haemophilus inﬂ uenzae (three cases). Excluding long-
term inpatients, pre-hospital antibiotics had been given 
to 23 of the 65 children who died (35% of deaths). All 
inpatients received antibiotics. Most patients admitted 
received intravenous antibiotics within 48 h of admission 
(43 of 45; 96%) or within 48 h of symptom onset for long-
term inpatients (three of ﬁ ve; 60%). One case of 
myocarditis was reported. According to clinical reports or 
death certiﬁ cation, acute respiratory distress syndrome 
occurred in 20 children. Intravenous corticosteroids were 
given in 18 cases.
Death certiﬁ cates were available for 66 cases. In 
46 (70%) cases, pandemic inﬂ uenza A H1N1 or a synonym 
was recorded as the direct cause of death. In seven (11%) 
cases, pandemic inﬂ uenza A H1N1 or a synonym was 
recorded as contributing to death. There was no record of 
pandemic inﬂ uenza A H1N1 on 13 death certiﬁ cates; in 
ﬁ ve of which, positive virological test results were 
received after the death certiﬁ cate was issued.
Discussion
Our report of the 70 deaths in children in England related 
to pandemic inﬂ uenza A H1N1 has shown that mortality 
disproportionately aﬀ ects ethnic minorities and those 
with pre-existing disorders. Many deaths occurred before 
hospital admission, especially in healthy children or 
those with only mild pre-existing disorders.
The overall childhood mortality rate for pandemic 
inﬂ uenza A H1N1 reported here (six per million 
population) is close to that for the Netherlands (ﬁ ve per 
million population for children under 14 years9) but lower 
than that in Argentina (11 per million population).3 A high 
disease burden was reported in the southern hemisphere 
because the pandemic coincided with the inﬂ uenza 
season in that region. Delayed presentation and 
unrecognised illness might have contributed further to 
the high mortality rate in Argentina.3 Mortality from 
seasonal inﬂ uenza in children is lower than that reported 
for pandemic inﬂ uenza A H1N1. Extrapolated data from 
population mortality estimates in England show a 
mortality rate from seasonal inﬂ uenza of two per million 
population for children aged less than 14 years,10 which is 
much the same as for international estimates.11 The occur-
rence of 70 deaths from pandemic inﬂ uenza A H1N1 in 
children in 1 year in England is greater than the number 
of deaths in children every year from leukaemia, and this 
high childhood mortality was last seen for a single 
infectious disease (meningococcal disease) in 2001.12
We identiﬁ ed the highest population mortality and 
case-fatality rates in children aged less than 1 year. A 
similar pattern has been reported from other countries.3 
The high population mortality rates that we identiﬁ ed 
among Bangladeshi and Pakistani groups are consistent 
with a US report that ethnic minority groups were 
disproportionately aﬀ ected by severe illness.13 This 
ﬁ nding might be attributable to clustering of pandemic 
inﬂ uenza A H1N1 cases in areas of England with high 
ethnic minority populations (such as London and the 
West Midlands),2 although other areas with lower ethnic 
minority populations such as the East Midlands and 
Yorkshire were also greatly aﬀ ected. An increased 
occurrence of pre-existing disorders might exist in ethnic 
minority children, although no reliable data are available 
to assess this claim. The extent to which ethnic origin 
itself, through genetic or cultural factors, confers 
increased susceptibility to severe illness or death remains 
unclear, and further investigation is needed.
We identiﬁ ed two distinct clinical patterns for deaths in 
children from pandemic inﬂ uenza A H1N1. The ﬁ rst 
group had early deterioration with death before hospital 
admission—mainly children with no or mild pre-existing 
disorders. Although these patients had not presented late 
to medical services, the threshold for hospital admission 
of these children is likely to have been higher than for 
those with severe pre-existing disorders. These children 
might have been cared for at home in the expectation 
that their illness would be self-limiting. Children dying 
early did not have more co-existing bacterial infection 
than those who died later, implying that these children 
had severe acute viral infection. A fulminant course has 
previously been described in a cohort of children with 
pandemic inﬂ uenza A H1N1 infection who were admitted 
to critical care after presenting with shock.14 The 
mechanism of organ failure in these children is unclear. 
However, they did have a substantially greater frequency 
of nausea or vomiting at or before presentation, which 
could indicate extensive viral replication, leading to early 
deterioration and death.15–17
The second group of deaths was children with severe 
underlying disorders who deteriorated during hospital 
admission. Those with neurological disease, particu-
larly cerebral palsy, were at high risk, as described in the 
USA.4 However, we also noted a high frequency of 
Deaths Population prevalence 
estimates (thousands)
Age-standardised mortality rate per 
million population (95% CI)
Chronic respiratory disease 33 392 167 (89–268)
Chronic cardiac disease 16 72 232 (132–377)
Chronic neurological disease 35 31 1536 (988–2242)
Immunosuppression 7 38 166 (66–343)
Chronic kidney disease 3 6 449 (85–1333)
Diabetes mellitus 0 2 0 (–)
None 13 10 125 1·3 (0·7–2·2)
Table 5: Age-standardised mortality rate for deaths related to pandemic inﬂ uenza A H1N1 for children 
aged between 6 months and 18 years with speciﬁ c pre-existing disorders 
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gastro-oesophageal reﬂ ux, gastrostomy feeding, and 
unsafe swallowing (when patients do not have a protective 
gag reﬂ ex) that frequently co-exist with severe cerebral 
palsy. The increased risk associated with chronic 
neurological disease might be explained partly by 
secondary aspiration and low respiratory reserves in these 
children. Because of small case numbers and no 
denominator data, the relative risk of death for cerebral 
palsy in the absence and presence of associated respiratory 
and gastrointestinal complications could not be assessed.
Good-quality data for chronic disease prevalence 
derived from the National Health Service primary care 
services enabled the calculation of disease-speciﬁ c 
mortality rates. Our analysis showed the highest 
population mortality rate in children with chronic 
neurological disease, consistent with the high proportion 
of children with neurological disease among the deaths. 
However, although absolute numbers of deaths from 
chronic kidney disease were low, the population rate of 
death was fairly high (although with wide conﬁ dence 
intervals) because of a low population prevalence.
We noted that asthma was present in only 7% of 
paediatric deaths. The prevalence of childhood asthma in 
England is estimated at up to 14%.18 Other investigators 
have suggested that asthma is associated with increased 
mortality from pandemic inﬂ uenza A H1N1 in children3 
and adults.9 Our ﬁ ndings contradict this notion. Although 
there were deaths in children with asthma, the high 
population prevalence of asthma will lower the disease-
speciﬁ c mortality rate. An explanation for our observa tions 
might be that asthma does not increase the risk of death. 
Alternatively, there might have been a low threshold for 
admission and aggressive therapy in these patients because 
of clinical and parental concern; this explanation is lent 
support by the high numbers of children with asthma who 
were admitted to hospital and critical care during the 
pandemic.3,19 If this explanation is true, a wider use of early 
aggressive treatment measures could reduce mortality.
Our study conﬁ rms that most children who died 
presented with typical respiratory symptoms rather than 
atypical features that could aid prognosis. Thrombo-
cytopenia and relative lymphopenia, however, might be 
early predictors of severe illness in children, which lends 
support to similar ﬁ ndings in adults20 and children treated 
in hospital.21 Conﬁ rmed bacterial infection was present in 
20% of cases in our study—mainly pneumonia, which is 
in accord with data for this pandemic in the USA4 and for 
seasonal inﬂ uenza,22 with similar pathogens described. 
Early treatment with antibiotics in children with clinical 
deterioration is important.23
Only 10% of children in this study received antiviral 
therapy within 48 h of symptom onset, which is a similar 
number to reports from Argentina in children treated in 
hospital.3 Antiviral use for the treatment of inﬂ uenza in 
children is controversial.24 However, these drugs are most 
eﬀ ective if given within 48 h of symptom onset.25 Our 
ﬁ ndings suggest that children with pre-existing disorders 
are at an increased risk of death. For many of these 
children, antiviral therapies are one of only a few 
therapeutic options available if the children are not 
vaccinated. Although our study was not designed to assess 
antiviral use, early treatment with antiviral therapy might 
maximise the eﬀ ectiveness of this treatment. This approach 
is especially important in primary care because 27% of 
children in our study died before admission to hospital. 
Further investigation into the contribution of pre-hospital 
antivirals to the outcome of aﬀ ected children is needed.
Our ﬁ ndings support the vaccination of children 
against pandemic inﬂ uenza A H1N1. Children at greatest 
risk of severe illness or death should be prioritised. Our 
data indicate that risk groups include children with pre-
existing illness (including chronic neurological or 
gastrointestinal disease) and those in ethnic minority 
groups (including Bangladeshi and Pakistani children). 
However, our ﬁ ndings also suggest that protection cannot 
be conﬁ ned to risk groups as 21% of deaths in our cohort 
occurred in healthy children.
Complete death ascertainment is diﬃ  cult to achieve. 
However, we believe our reporting system achieved a 
high level. We have classiﬁ ed deaths according to those 
occurring before and subsequent to inpatient admission. 
This classiﬁ cation will not capture deaths occurring 
within hours of hospital admission; therefore, the true 
early death group might be larger. By using formal 
hospital admission, we have been able to examine deaths 
occurring too rapidly to enable stabilisation.
Case-fatality rates are subject to limitations.5 Case 
estimates in England take into account laboratory-
conﬁ rmed cases in primary care, in addition to estimates 
of the proportion of symptomatic individuals who do not 
seek medical attention. The estimates of case fatality in 
this study have wide ranges, indicating uncertainty about 
those not seeking medical help. If this proportion is 
higher than estimated, our case-fatality rates might be 
an overestimate. However, this method of case estimation 
is likely to provide a more meaningful denominator for 
case fatality than use of laboratory-conﬁ rmed cases.
Few countries hold comprehensive prevalence data for 
chronic diseases in the population. The National Health 
Service has a strong primary care system and a 
longstanding vaccination programme that relies on 
pooled data for the occurrence of risk factors. Although 
these data are derived from a sample of clinical practices, 
we believe that they provide reliable estimates of 
prevalence. Additionally, we have interpreted derived 
mortality rates comparatively rather than in absolute 
terms. More extensive comparisons of risk would be 
possible with a control group.
Although this is a large study of paediatric deaths 
related to pandemic inﬂ uenza A H1N1, more detailed 
analysis would be possible with higher case numbers. 
An international study that pooled data on childhood 
deaths from pandemic inﬂ uenza A H1N1 would be 
greatly informative.
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